Pasithea Therapeutics Corp (KTTA): Kapitalisasi marang bathi resik kanthi nimbang wutah

Risks for Pasithea Therapeutics (KTTA) are linked to the lack of recurring revenue and the potential failure of psychiatric developments. An upward trend in the P/E ratio serves as an indicator of stability, where 0.00 determines this parameter level. High patient loyalty at ketamine centers and strict DEA control ensure stability, while asset value is based on client flow and successes in PTSD therapy.

The market value of Pasithea Therapeutics (KTTA) depends directly on the success of clinical trials for brain disorder therapies and the volume of R&D funding. By analyzing the PEG ratio, an investor compares the current P/E multiple with the earnings growth rate: a value below one signals that the asset is undervalued relative to its expansion, confirming the sustainability of the biotech's business model.